pyrazines has been researched along with Blast Phase in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Fujisawa, S; Harada, S; Izumiyama, K; Kondo, T; Mori, A; Morioka, M; Ogasawara, R; Onozawa, M; Saito, M; Teshima, T | 1 |
Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D | 1 |
Cao, R; He, H; Huang, KK; Jiang, XJ; Liao, LB; Lin, R; Meng, FY; Wang, Q; Wu, FQ; Xu, D; Yang, M; Yi, ZS; Yin, CX; Zheng, ZX; Zhou, HS | 1 |
Dai, Y; Grant, S; Rahmani, M | 1 |
4 other study(ies) available for pyrazines and Blast Phase
Article | Year |
---|---|
Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of
Topics: Adolescent; Aniline Compounds; Biopsy; Blast Crisis; Bone Marrow; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Monocytes; Protein Kinase Inhibitors; Pyrazines; Radiography, Thoracic; Tandem Repeat Sequences | 2021 |
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Topics: Adult; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Boronic Acids; Bortezomib; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrazines; Pyrimidines; RNA Interference; S-Phase Kinase-Associated Proteins; Young Adult | 2012 |
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blast Crisis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, Myeloid, Acute; Leupeptins; Mitogen-Activated Protein Kinases; Multienzyme Complexes; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2003 |